327 related articles for article (PubMed ID: 36142332)
1. Common and Rare
Hsu LA; Teng MS; Wu S; Chou HH; Ko YL
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142332
[TBL] [Abstract][Full Text] [Related]
2. Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis.
Pott J; Kheirkhah A; Gadin JR; Kleber ME; Delgado GE; Kirsten H; Forer L; Hauck SM; Burkhardt R; Scharnagl H; Loeffler M; März W; Thiery J; Gieger C; Peters A; Silveira A; Hooft FV; Kronenberg F; Scholz M
Biol Sex Differ; 2024 Mar; 15(1):26. PubMed ID: 38532495
[TBL] [Abstract][Full Text] [Related]
3. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
4. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
Hong P; Han L; Wan Y
Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
[TBL] [Abstract][Full Text] [Related]
6. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
7. Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.
Pham K; Mulugeta A; Lumsden A; Hyppӧnen E
Br J Clin Pharmacol; 2023 Oct; 89(10):2992-3004. PubMed ID: 37208559
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic Effects of
Jang SJ; Tuan WL; Hsu LA; Er LK; Teng MS; Wu S; Ko YL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499290
[TBL] [Abstract][Full Text] [Related]
9. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
10. Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization.
Chang YC; Hsu LA; Ko YL
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834124
[TBL] [Abstract][Full Text] [Related]
11. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations.
Ardissino M; Slob EAW; Reddy RK; Morley AP; Schuermans A; Hill P; Williamson C; Honigberg MC; de Marvao A; Ng FS
Eur J Prev Cardiol; 2024 Jun; 31(8):955-965. PubMed ID: 38294056
[TBL] [Abstract][Full Text] [Related]
12. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
13. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
14. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank.
Wang Q; Wang Y; Lehto K; Pedersen NL; Williams DM; Hägg S
EBioMedicine; 2019 Jul; 45():487-494. PubMed ID: 31300347
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Schmidt AF; Swerdlow DI; Holmes MV; Patel RS; Fairhurst-Hunter Z; Lyall DM; Hartwig FP; Horta BL; Hyppönen E; Power C; Moldovan M; van Iperen E; Hovingh GK; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Liu T; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott R; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Husemoen LL; Grarup N; Pedersen O; Hansen T; Linneberg A; Simonsen KS; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Kirchner HL; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Smith DJ; Meade T; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Balkau B; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Ridker PM; Chasman DI; Reiner AP; Lange LA; Ritchie MD; Asselbergs FW; Casas JP; Keating BJ; Preiss D; Hingorani AD; ; Sattar N
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):97-105. PubMed ID: 27908689
[TBL] [Abstract][Full Text] [Related]
16. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
17. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.
Cupido AJ; Reeskamp LF; Hingorani AD; Finan C; Asselbergs FW; Hovingh GK; Schmidt AF
JAMA Cardiol; 2022 Sep; 7(9):955-964. PubMed ID: 35921096
[TBL] [Abstract][Full Text] [Related]
18. Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9.
Lin L; Yu H; Xue Y; Wang L; Zhu P
BMC Med Genomics; 2024 Feb; 17(1):59. PubMed ID: 38383373
[TBL] [Abstract][Full Text] [Related]
19. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
20. Circulating chemerin levels are determined through circulating platelet counts in nondiabetic Taiwanese people: A bidirectional Mendelian randomization study.
Hsu LA; Chou HH; Teng MS; Wu S; Ko YL
Atherosclerosis; 2021 Mar; 320():61-69. PubMed ID: 33545615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
